Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥12 years (only 18 and above in Russia)~* Documented diagnosis of congenital fibrinogen deficiency, expected to require on-demand treatment for bleeding or surgical prophylaxis:~* Fibrinogen deficiency manifested as afibrinogenaemia or severe hypofibrinogenaemia.~* Historical plasma fibrinogen activity of \<50 mg/dL or levels below the limit of detection of the local assay method.~* Expected to have an acute bleeding episode (spontaneous or after trauma) or planning to undergo elective surgery.~* Informed consent signed by the subject or legal guardian.~Exclusion Criteria:~* Life expectancy \<6 months.~* Bleeding disorder other than congenital fibrinogen deficiency, including dysfibrinogenaemia.~* Prophylactic treatment with a fibrinogen concentrate.~Treatment with:~* Any fibrinogen concentrate or other fibrinogen-containing blood product within 2 weeks prior to start of treatment for the bleeding episode or surgery.~* Any coagulation-active drug (i.e., non-steroidal anti-inflammatory drugs, warfarin, coumarin derivatives, platelet aggregation inhibitors) within 1 week prior to start of treatment for the bleeding episode or surgery, or as a planned or expected medication during the time period from Day 1 until 24 hours (i.e., 1 day) after the last Octafibrin infusion.~Presence or history of:~* Hypersensitivity to study medication.~* Deep vein thrombosis or pulmonary embolism within 1 year prior to start of treatment for the bleeding episode or surgery.~* Arterial thrombosis within 1 year prior to start of treatment for the bleeding episode or surgery~* Hypersensitivity to human plasma proteins.~* Oesophageal varicose bleeding.~* End-stage liver disease (i.e., Child-Pugh score B or C).~Pregnant women within the first 20 weeks of gestation.~Currently breast-feeding.~Known positive HIV infection with a viral load \>200 particles/μL or \>400,000 copies/mL.~Polytrauma 1 year prior to start of treatment for the bleeding episode or surgery.~Diagnosis or suspicion of a neutralizing anti-fibrinogen inhibitor currently or any time in the past.~Acute or chronic medical condition which may, in the opinion of investigator, affect the conduct of the study, including~* Subjects receiving immune-modulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to \>10 mg/day), or similar drugs at study start.~* Subjects having evidence or a history (within the previous 12 months) of abuse of any licit or illicit drug substance.~Participation in another interventional clinical study currently or during the past 4 weeks.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octafibrin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).